Page 138 - 《中国药房》2022年5期

tients[J]. Antimicrob Agents Chemother，2020，64（9）： （12）：e01545-e01520.
e00905-e00920. [31] ALIHODZIC D，BROEKER A，BAEHR M，et al. Impact
[21] HALL R G 2nd，SWANCUTT M A，MEEK C，et al. of inaccurate documentation of sampling and infusion
Weight drives caspofungin pharmacokinetic variability in time in model-informed precision dosing[J]. Front Phar-
overweight and obese people：fractal power signatures be- macol，2020，11：172.
yond two-thirds or three-fourths[J]. Antimicrob Agents [32] LI F Y，ZHOU M G，JIAO Z，et al. Caspofungin pharma-
Chemother，2013，57（5）：2259-2264. cokinetics and probability of target attainment in ICU
[22] MARTIAL L C，BRÜGGEMANN R J M，SCHOUTEN J A， patients in China[J]. J Glob Antimicrob Resist，2021，25：
et al. Dose reduction of caspofungin in intensive care unit 238-263.
patients with Child Pugh B will result in suboptimal expo- [33] MORRIS M I，VILLMANN M. Echinocandins in the mana-
sure[J]. Clin Pharmacokinet，2016，55（6）：723-733. gement of invasive fungal infections，part 2[J]. Am J
[23] KURLAND S，FUREBRING M，LÖWDIN E，et al. Phar- Health Syst Pharm，2006，63（19）：1813-1820.
macokinetics of caspofungin in critically ill patients in re- [34] KOFLA G，RUHNKE M. Pharmacology and metabolism
lation to liver dysfunction：differential impact of plasma of anidulafungin，caspofungin and micafungin in the treat-
albumin and bilirubin levels[J]. Antimicrob Agents Che- ment of invasive candidosis：review of the literature[J].
mother，2019，63（6）：e02466-e02418. Eur J Med Res，2011，16（4）：159-166.
[24] GUSTOT T，TER HEINE R，BRAUNS E，et al. Caspofun- [35] LEWIS R E. Current concepts in antifungal pharmacology
gin dosage adjustments are not required for patients with [J]. Mayo Clin Proc，2011，86（8）：805-817.
Child-Pugh B or C cirrhosis[J]. J Antimicrob Chemother， [36] ANDES D，DIEKEMA D J，PFALLER M A，et al. In vivo
2018，73（9）：2493-2496. comparison of the pharmacodynamic targets for echino-
[25] ROGER C，WALLIS S C，MULLER L，et al. Caspofungin candin drugs against Candida species[J]. Antimicrob
population pharmacokinetics in critically ill patients un- Agents Chemother，2010，54（6）：2497-2506.
dergoing continuous veno-venous haemofiltration or hae- [37] ANTACHOPOULOS C，MELETIADIS J，SEIN T，et al.
modiafiltration[J]. Clin Pharmacokinet，2017，56（9）： Concentration-dependent effects of caspofungin on the
1057-1068. metabolic activity of Aspergillus species[J]. Antimicrob
[26] PÉREZ-PITARCHA，FERRIOLS-LISART R，AGUILAR G， Agents Chemother，2007，51（3）：881-887.
et al. Dosing of caspofungin based on a pharmacokinetic/ [38] POUND M W，TOWNSEND M L，DREW R H. Echino-
pharmacodynamic index for the treatment of invasive fun- candin pharmacodynamics：review and clinical implica-
gal infections in critically ill patients on continuous veno- tions[J]. J Antimicrob Chemother，2010，65（6）：1108-
venous haemodiafiltration[J]. Int J Antimicrob Agents， 1118.
2018，51（1）：115-121. [39] MASTERTON R G，KUTI J L，TURNER P J，et al. The
[27] WANG Q L，ZHANG Z，LIU D L，et al. Population phar- OPTAMA programme：utilizing MYSTIC（2002）to pre-
macokinetics of caspofungin among extracorporeal mem- dict critical pharmacodynamic target attainment against
brane oxygenation patients during the postoperative period nosocomial pathogens in Europe[J]. J Antimicrob Che-
of lung transplantation[J]. Antimicrob Agents Chemother， mother，2005，55（1）：71-77.
2020，64（11）：e00687-e00620. [40] XU G Q，ZHU L Q，LIAO S S，et al. Assessment of echi-
[28] WÜRTHWEIN G，YOUNG C，LANVERS-KAMINSKY C， nocandin regimens by pharmacokinetic/pharmacodynamic
et al. Population pharmacokinetics of liposomal amphoteri- analysis against Candida spp. in paediatric patients[J]. Int
cin B and caspofungin in allogeneic hematopoietic stem J Antimicrob Agents，2015，46（6）：631-641.
cell recipients[J]. Antimicrob Agents Chemother，2012，56 [41] YANG Q T，WANG T T，XIE J，et al. Pharmacokinetic/
（1）：536-543. pharmacodynamic adequacy of echinocandins against
[29] BORSUK-DE MOOR A，SYSIAK-SŁAWECKA J，RYPULAK Candida spp. in intensive care unit patients and general
E，et al. Nonstationary pharmacokinetics of caspofungin patient populations[J]. Int J Antimicrob Agents，2016，47
in ICU patients[J]. Antimicrob Agents Chemother，2020， （5）：397-402.
64（9）：e00345-e00320. [42] ADEMBRI C，VILLA G，ROSI E，et al. Caspofungin PK
[30] BAILLY S，GAUTIER-VEYRET E，LÊ M P，et al. Impact in critically ill patients after the first and fourth doses：sug-
of loading dose of caspofungin in pharmacokinetic-phar- gestions for therapeutic drug monitoring?[J]. J Chemother，
macodynamic target attainment for severe candidiasis in- 2020，32（3）：124-131.
fections in patients in intensive care units：the CASPO- （收稿日期：2021-09-23 修回日期：2022-01-22）
LOAD study[J]. Antimicrob Agents Chemother，2020，64 （编辑：唐晓莲）

·640 · China Pharmacy 2022 Vol. 33 No. 5 中国药房 2022年第33卷第5期